Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASC
Go back to Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASC| Merck & Co. (NYSE: MRK) | Delayed: 119.60 +4.12 (3.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $115.48 | 52 Week High | $65.46 | |||
| Open | $116.53 | 52 Week Low | $47.97 | |||
| Day High | $119.80 | P/E | 81.36 | |||
| Day Low | $116.53 | EPS | $1.47 | |||
| Volume | 11,893,692 | |||||
| Marina Biotech, Inc. (NASDAQ: MRNA) | Delayed: 61.00 +1.65 (2.78%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $59.35 | 52 Week High | $0.52 | |||
| Open | $59.05 | 52 Week Low | $0.08 | |||
| Day High | $63.98 | P/E | N/A | |||
| Day Low | $58.34 | EPS | $-3.80 | |||
| Volume | 6,829,430 | |||||
